The t(9;11)(p22;q23) is the most common chromosomal translocation in topoisomerase II inhibitor therapy-related acute myeloid leukemia (tAML). This translocation fuses the MLL and AF9 proto-oncogenes producing a novel chimeric protein. In order to gain insight into the mechanism generating the t(9;11) and to clarify the role topoisomerase II inhibition may play in that mechanism we have cloned and sequenced the breakpoints from four tAML patients with the t(9;11). This sequence analysis identifies topoisomerase II consensus binding sequences near or at the chromosome 11 and chromosome 9 breakpoints in all four patients. One patient also had the consensus binding sequence for the TRANSLIN DNA-binding protein at the 9p22 and 11q23 breakpoints. Our results further support a direct role for topoisomerase II in the genesis of these tAML translocations.
Introduction
Topoisomerase II inhibitors are an important group of chemotherapeutic agents in the treatment of both solid tumors and hematologic malignancies. 1 However, they are associated with therapy-related (secondary) leukemias. [2] [3] [4] This complication is a major challenge to clinicians trying to use them to improve cure rates for patients with high risk malignancies. Unlike the therapy-related leukemias reported after treatment with alkylators, therapy-related leukemias associated with topoisomerase II inhibitors are characterized by a shorter time to onset, lack a preceding myelodysplastic phase, lack abnormalities of 5q and 7q, and usually show monocytic differentiation. 2, 3 The topoisomerase II inhibitors implicated in therapy-related leukemia such as etoposide, teniposide and doxorubicin, stabilize the 'cleavable complex' formed by the enzyme and DNA when the religation step catalyzed by topoiosomerase II is blocked. This causes double stranded DNA breaks and eventual cell death by apoptosis 5 but may also contribute to gene recombination and resultant secondary malignancy. [6] [7] [8] A better understanding of the topoisomerase II inhibitors' mechanism of leukemogenesis might lead to clinically useful ways to diminish this effect.
The mixed lineage leukemia (MLL) gene, located on chromosome 11 at band q23, is the gene most commonly involved in topoisomerase II inhibitor related secondary leukemias. [9] [10] [11] [12] These may be acute lymphocytic leukemias (ALL) but are typically acute myeloid leukemias (AML). [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] MLL is involved in balanced translocations which produce in-frame fusion genes with one of multiple partner genes. The breakpoints of these translocations occur within a breakpoint cluster region (bcr) spanning an 8.3 kb BamHI fragment in the middle of MLL. 13, 14 The mechanism for translocation and clustering are not clearly understood, but topoisomerase II binding/cleavage sites have been implicated. 8, 12, 15 In prior work, a topoisomerase II consensus binding sequence described by Spitzner and Muller 16 was identified by us to be within 4 base pairs of the breakpoint of a therapy-related acute lymphoblastic leukemia patient with a t(4;11). 12 Aplan et al 8 noted that cells from a T cell ALL patient, treated with doxorubicin had an in vivo topoisomerase II inhibitor induced DNA cleavage near MLL exon 9. We observed similar in vivo topoisomerase II inhibitor induced cleavages sites using several myeloid cell lines (Ref. 12 and Strissel et al 41 ). Multiple in vitro topoisomerase II cleavage sites were produced in a clone of MLL intron 6 fragment by Felix et al 15 after incubation with topoisomerase II, epipodophyllotoxin and ATP. One of these coincided with a de novo AML t(9;11) breakpoint. Strissel-Broeker et al 17 noted that within the MLL bcr, six of seven topoisomerase II consensus binding sequences fall in an MLL intron 8 scaffold attachment region (SAR). Scaffold attachment region chromatin is typically rich in topoisomerase II alpha. 5 Interestingly, the same area is also where 75% of MLL/11q23 secondary leukemia breakpoints occur whereas only 25% of de novo leukemias' MLL breakpoints occur in this portion of the bcr. 17 While theories implicating the topoisomerase II consensus binding and cleavage sequences in the mechanism of translocation are attractive they have yet to be proven. Furthermore, there exists the possibility that other recombinogenic sequences may exist which promote translocations. For instance, one of us (PD) discovered a 7/8 -like motif 18 at the breakpoint of a de novo t(4;11) translocation.
14 Alu sequences have also been noted at MLL breakpoints and Alu-mediated homologous recombination has been postulated as a mechanism for MLL rearrangement. 19 Additional motifs, such as the heptamer-nonamer V-D-J recombinase signal, 20 loop-forming, guanine-rich elements, 21 and the consensus TRANSLIN binding sequence 22 might also be involved in MLL translocations. To investigate these questions further, we sequenced four additional patient breakpoints from a series of therapy-related leukemias with MLL rearrangement we had previously described. 12 In order to clone these breakpoints from minimal amounts of DNA, we employed a polymerase chain reaction (PCR)-based technique. Because of the length of the MLL bcr we were unable to use conventional PCR and instead employed the long range-PCR (LR-PCR) method of Cheng et al 23 which allows reliable PCR amplification of products of over 10 kb. We also show t(9;11) DNA LR-PCR to be quite sensitive, suggesting that it may be useful in the detection of minimal residual disease.
Long range-polymerase chain reaction
A control LR-PCR 23 reaction was performed on all DNA to demonstrate it could serve as a PCR template. The primers used to amplify the control products are MLL-LA and MLL-9AS and amplify a 4476 base pair product from the MLL bcr. The MLL-LA sequence is found in MLL exon 7 and the MLL-9AS sequence is found in MLL exon 9. The sequence of these primers with the base pair positions in the MLL/11q23 bcr based on the sequence of Gu et al 24 are: MLL-LA, 5Ј AGT CCA CAG GAT CAG AGT GGA CTT TAA 3Ј (2457-2484); MLL-9AS, 5Ј TTG TAG CCT GAT GTT 3Ј (6932-6918). The primers used to amplify the der(11) breakpoint products are MLL-LA, MLL-RT, and AF9-G1. The MLL-RT sequence is found in exon five of the MLL gene and the AF9-G1 sequence 25 is found in an exon of the AF9 gene on chromosome 9: MLL-RT, 5Ј AAG CAG CCT CCA CCA CCA GAA TCA 3Ј (239-263); AF9-G1, 5Ј GCT GGT AGG ACT GGG TTG TTC AGA 3Ј.
LR-PCR was performed on DNA from the t(9;11) patients using the GeneAmp XL PCR Kit (Perkin-Elmer, Branchburg, NJ, USA). The XL thermostable DNA polymerase activity was specifically designed for long range PCR and contains both rTth polymerase and the Vent proofreading polymerase. The breakpoints were amplified using 100 l reaction mixtures in 25 mM Tricine, pH 8.7/85 mM KOAc/9.6% glycerol/0.2 mM of all four dNTPs/1.1 mM Mg(OAc) 2 /4 units of rTth polymerase/0.9 units of Vent polymerase/400 pg per l of each primer/DNA concentration 10-40 ng per l. The nont(9;11) cell line MV4; 11 26 was used as a source of negative control DNA. The thermal cycling profile consisted of an initial hot start and denaturation at 94°C for 1 min followed by 32 cycles of denaturation at 94°C for 15 s, annealing and extension at 60°C for 10 min, with a 15 s segment elongation for the last 17 cycles; and a final elongation at 72°C for 10 min. The PCR thermal cycler used was a PTC-100 Programmable Thermal Controller (MJ Research, Watertown, MA, USA). To assess for the sensitivity of LR-PCR, t(9;11) containing DNA from patients No. 6 and No. 3 were serially diluted with deionized water and added to MV4;11 DNA (negative control DNA). All experiments were reproduced at least once.
Hybridization
LR-PCR products were analyzed by electrophoresis in 0.8% agarose and the gels stained with ethidium bromide. Southern transfer to Hybond-N + nylon filters (Amersham, Arlington Heights, IL, USA), was performed as recommended by the manufacturer. Hybridization to the Southern blots was performed using a random primed MLL/11q23 breakpoint cluster region genomic probe P/S4 14 or the 32 P end-labeled oligonucleotide probes AF9-G1 Rev (an intronic AF9 oligo nucleotide determined by sequence analysis described below) and MLL-RT2. 24 The oligonucleotide sequences are: AF9-G1 Rev, 5Ј AGG GAG ACC TGT ATA GCA G 3Ј; MLL-RT2, 5Ј CTC TGT GCC AGT AGT GGG CAT 3Ј (3121-3142). The MLL bcr probe P/S4 14 hybridizations were done in 50% formamide at 43°C and washed to a final stringency of 0.1 × SSC, 0.1% SDS at 55°C. Oligonucleotide hybridizations were done at 37°C and washed to a final stringency of 0.1 × SSPE, 0.1% SDS at 37°C.
DNA sequence analysis of LR-PCR products
PCR products were purified using the Promega Wizard PCR purification kit (Promega Corporation, Madison, WI, USA). The purified DNA was then resuspended in 50 l of deionized water. Nucleotide sequences were determined by the dideoxy chain-termination method using dsDNA Cycle Sequencing System (Life Technologies, Gaithersburg, MD, USA). For initial sequence analysis the patient 3 product was sequenced using the AF9-G1 primer. The sequence generated from this was then used in somatic cell hybrid PCR mapping (see below.) For breakpoint sequencing, primers were generated from the MLL bcr sequence. 24 
Somatic cell hybrid analysis
The patient 3 sequence described above was used to generate PCR primers to map the chromosomal origin of the telomeric end of the LA-PCR product. The primers used were AF9G1 Rev, and AF9G1N: AF9-G1 Rev, 5Ј AGG GAG ACC TGT ATA GCA G 3Ј; AF9G1N, 5Ј CGG GAT ACC ACA CAT CTA A 3Ј. The template used was 100 ng of normal human DNA, human-hamster somatic hybrids containing only human chromosome 9 or 11 (clones NA10611 or NA10927A; Coriell Institute, Camden, NJ, USA) PCR was done using Taq polymerase and standard conditions. The thermal cycling profile consisted of an initial denaturation at 94°C for 5 min, 30 cycles of 94°C for 1 min, 55°C for 1 min, and 70°C for 1 min. The PCR products were then analyzed by electrophoresis in a 1% agarose gel.
Cloning and sequencing of germline AF9
A 200 base pair probe from chromosome 9-derived sequence from the genomic breakpoint of a t(9;11) patient was used to screen a cosmid library of J64051 DNA (gift of Lawrence Livermore National Laboratory). The entire sequence of this cosmid was determined using the previously described random cloning method 27, 28 employing universal and custom synthetic primers. This sequence has been deposited in the GenBank database (Accession No. 000007).
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Results
LR-PCR amplification of t(9;11) der(11) breakpoints
To assess the usefulness of LR-PCR in detecting chromosomal rearrangements, we amplified DNA from six patients previously described by us 12 with therapy-related acute myeloid leukemia (tAML) and known t(9;11) translocations (Table 1) . We sought to amplify the der(11) product as this is the likely oncogenic fusion product. 13 Using MLL-RT and MLL-LA as sense primers and AF9-G1 as the anti-sense primer (Figure 1 ) we successfully generated LR-PCR products from 5/6 patients ( Figure 2a ) with products ranging in size from 2.3 to 15 kb. The single case not amplified by LR-PCR may have an AF9 breakpoint telomeric of the primer or the potential product may exceed the limits of LR-PCR.
To confirm the validity of these products, we hybridized them with the MLL bcr probe P/S4. 14 The amplified bands from patients 3, 5, 10 and 11 all hybridized to P/S4 ( Figure  2b ). The patient 6 breakpoint was later determined by sequencing (below) to be 5Ј of P/S4, explaining why it did not hybridize. To confirm that these PCR products were the result of amplification of the t(9;11), we directly sequenced the region closest to the AF9-G1 primer from patient 3. This sequence did not contain AF9 exonic sequence. Therefore its chromosome 9 origin was confirmed by conventional PCR analysis using DNA derived from human-hamster somatic cell hybrids containing either chromosomes 9 or 11 as their sole human chromosomes (Figure 2c) . From this sequence an oligonucleotide probe was prepared and used to confirm that the other four patients' LR-PCR products contained sequences of chromosome 9 origin (not shown). In addition, later sequence analysis determined this region to be from AF9 intronic sequence (see below). There was not adequate residual material from any of the patients to clone the der(9) breakpoint.
Sensitivity of LR-PCR detection of the t(9;11)
For LR-PCR to be of use in the diagnosis and management of patients with hematologic neoplasms, it should have sensitivity comparable to conventional DNA PCR or RT-PCR and should certainly be more sensitive than Southern analysis. In order to assess the sensitivity of LR-PCR under conditions similar to those when assaying for minimal residual disease, we serially diluted t(9;11) patient DNA into DNA from the nont(9;11) AML cell line, MV411. 26 Our studies examining two separate patients using either MLL primer and LR-PCR with Southern blot indicate that a sensitivity of 1 in 10 000 is reliably obtainable (Figure 3a-c) . This is 100-fold more sensitive than Southern blot. In addition, experiments with material from patient 6 were able to detect t(9;11) LR-PCR product at 1 in 500 000 dilution (Figure 3b ). The sensitivity did not correlate with the size of the product. Repeated attempts to assess the ability to detect the relatively small der(11) LR-PCR product from patient 3 only yielded a maximum sensitivity of 1:10 000 (Figure 3a) .
Breakpoint sequence analysis
To gain better insight into the mechanism of translocation we determined the DNA sequence at the der(11) breakpoint from four of the patients whose samples produced abundant LR-PCR products. The LR-PCR products from these patients were purified and directly cycle sequenced using primers generated from the published MLL/11q23 bcr sequence of Gu et al. 24 This allowed the determination of the DNA sequence at the der(11) breakpoints and their location within the germline MLL/11q23 sequence (Figures 1 and 4) . In order to determine the normal AF9/9p22 sequence at t(9;11) breakpoints a genomic cosmid of the region was isolated and sequenced (described in detail in Ref. 29) . Comparison of this sequence with the der(11) breakpoints sequences and AF9 cDNA sequence 25 allowed the localization of the breakpoints and the definition of the AF9 intron-exon structure in the region of the breakpoints (Figure 1) .
We searched for a consensus sequence between these four patients' sequences using the GCG programs LINEUP and PILEUP 30 but found none. The addition of the sequence from the therapy-related ALL-t(4;11) breakpoint we have previously described 12 also did not yield a consensus sequence. Short identical sequences of 1-3 base pairs are present at the breakpoints of patients 3, 5, and 6. Patient 10 has a recurrent CTT sequence on both germline 9 and 11 near the breakpoint. All of the MLL/11q23 breakpoints occur within intronic sequences and the MLL/11q23 breakpoints of patients 5 and 6 breakpoints are in class J Alu sequences. 24 Two MLL/11q23 breakpoints (patients 5 and 10) fall within the SAR described by Strissel-Broeker et al 17 and two do not. All of the AF9/9p22 breakpoints occurred in intronic sequences that are free of Alu repetitive elements.
Because of the potential role topoisomerase II may have played in mediating these translocations we examined the germline chromosome 9 and 11 sequence near the breakpoint for the Spitzner and Muller consensus sequence for vertebrate topoisomerase II binding (5Ј-RNYNNCNNGYNG(G/T) TNYNY, where 'R' represents purine, 'Y' represents pyrimidine, and 'N' any nucleotide). 16 For our comparisons we examined the sequences around the breakpoints for similarity to the 10 purine, pyrimidine or specific nucleotides (eg non 'N') in the consensus sequence. All patients had a 7-9/10 similarity ending within 40 base pairs (bp) of the breakpoint on both the germline chromosome 9 and 11 sequences. The chromosome 11 breakpoints of all patients had such a sequence within 7 basepairs of the breakpoint with patients 6 and 10 having 7/10 similarities overlapping their breakpoints. On chromosome 9, similarities of at least 8/10 nucleotides were present within 40 basepairs of the breakpoint with the region of similarity in patient 3 overlapping the breakpoint.
Additionally, we analyzed the sequences for evidence of other motifs implicated in DNA recombination in other tumors. A 7/8 -like motif (CC(A/T)CC(A/T)CG) 18 present on the normal chromosome 11 falls 14 bp centromeric to the breakpoint of patient 3. Only patient 5 exhibited sequences near the breakpoint similar to the antigen receptor heptamerspacer-nonamer motifs (CAC(A/T)GTG-N (12 or 23) -ACAAAAACC). 20 Patient 5 had a 7/7 heptamer separated by 22 base pairs from a 7/9 nonamer motif on chromosome 11 ending 23 bp before the breakpoint. In the chromosome 9 germline sequence there is a 5/7 heptamer separated by 11 base pairs from a 6/9 nonamer ending 12 bp before the breakpoint. Interestingly, this patient also exhibited a 12/15 match with a TRANSLIN consensus binding sequence 22 spanning the breakpoint in the germline MLL/11q23 sequence and in the germline AF9/9p22 sequence there is a 10/14 match to another form of the TRANSLIN consensus binding sequence 22 spanning the breakpoint.
Discussion
We report here our analysis of the sequence of four patients with t(9;11) therapy-related leukemias, all of whom had received prior therapy with topoisomerase II inhibitors. We embarked upon these analyses to improve our understanding of the process by which this class of chemotherapeutic agents contribute to gene rearrangement and ensuing secondary malignancy. The increasing usefulness of epipodophyllotoxins, one of which is now frequently used in high doses as a preparative agent for stem cell transplantation 31 and the continued importance of doxorubicin in curing a wide variety of neoplasms 1 suggests the incidence of secondary leukemias will increase. A better understanding of the molecular mechanism of leukemogenesis might reveal ways of preventing this problem.
In prior work we demonstrated two in vivo topoisomerase II inhibitor-induced cleavage sites within the MLL bcr in a myeloid cell line 12 and one of us (NZ-L) one of those sites in multiple cell lines. 41 Aplan et al 8 found in vivo cleavage after doxorubicin therapy in one patient as well as a number of other cell lines, the cleavage site mapping in the region of the one 100% identity topoisomerase II consensus binding sequence 17 in MLL. In vitro incubation with topoisomerase II, epipodophyllotoxin and ATP yielded multiple breaks in an MLL intron 6 clone and one of these cleavage sites corresponded to a reported de novo leukemia MLL translocation breakpoint. 15 Strissel-Broeker et al 17 noted that the majority of therapy-related leukemia MLL breakpoints occur within the scaffold attachment region of the MLL bcr. This appears to confirm the interplay of chromatin structure in the mechanism of translocation. These data suggest a direct role in topoisomerase II inhibition in the genesis of therapy-related leukemia MLL translocations because SARs are rich in topoisomerase II. A recent study 32 found that the MLL bcr SAR is also the site of the majority of breakpoints in infant MLL/11q23 leukemia. (a) Ethidium bromide stain of the LR-PCR products analyzed on a 0.8% agarose gel. PCR primers were MLL-LA and MLL-RT and the AF-9 primer AF-9G1 (see Figure 1) . B, no DNA negative control; M, MV4;11 cell line DNA (non-t(9;11) control); 1, 3, 5, 6, 10, 11, patient DNAs. (b) Southern blot of the LR-PCR gel shown in (a) hybridized with the MLL exon 8 genomic probe, P/S4. (c) Conventional PCR somatic cell hybrid analysis of the telomeric end of the LR-PCR product from patient 3. S, 100 base pair ladder size standard; B, no DNA negative control; H, normal human DNA positive control; 9, somatic cell hybrid containing human chromosome DNA 9 on a hamster background; 11, somatic cell hybrid containing human chromosome DNA 11 on a hamster background.
These authors suggest a similar mechanism may be operative in the genesis of infant and therapy-related MLL translocations.
The data in this report further implicate topoisomerase II by identifying the presence of a Spitzner and Muller 16 topoisomerase II consensus binding sequence in the germline MLL or AF9 sequences within 10 basepairs of the breakpoint in six of eight breakpoints and within 40 base pairs of the breakpoint in the other two (each der(11) translocation will have one MLL and one AF9 breakpoint). While this is provocative, the true significance is unclear. In vivo and in vitro sites of topoisomerase II inhibitor-induced cleavage may coincide, 33 however, chromatin structure may be the predominant determinant of binding and cleavage sites in intact cells. 34 Moreover, data from Felix et al 15 indicates that the Spitzner and Muller consensus sequence does not even accurately predict in vitro cleavage in the MLL bcr. Two of five MLL breakpoints we have cloned from therapy-related leukemias (Ref. 12 and this report) map centromeric of the MLL bcr SAR and Felix et al have recently determined two therapy-related ALL patients to have MLL breakpoints centromeric of the SAR. 35 These non-SAR breakpoints may be due to the influence of other unknown recombinogenic mechanisms but there too, topoisomerase II may play a fundamental role in the recombination process. Of our two non-SAR breakpoints, patient 3 received cylcophosphamide with etoposide and patient 6 received cyclophosphamide with doxorubicin. Topoisomerase II plays a role in the repair of DNA damaged by alkylating agents 36 and there is evidence it is recruited to DNA with alkylation damage. 37 The complex interplay of DNA repair mechanisms in the setting of topoisomerase II inhibition may be critical to the genesis of therapy-related leukemia translocations.
Figure 4
Der(11) breakpoint sequence in centromeric to telomeric orientation. Ch9, germline AF9/9p22 sequence; der(11), der(11) sequence; Ch11, germline MLL/11q23 sequence; single underline, -like sequence; double underline, antigen receptor-like heptamer/nonamer; sequences above and below represent topiosmerase II consensus binding sequence (RNYNNCNNGYNG(G/T)TNYNY) 16 and TRANSLIN binding consensus. 22 We also sought to examine other recombinogenic sequences that might be implicated in these translocations. There is a 7/8 -like sequence 18 in the MLL bcr close to the breakpoint of patient 3. We previously found another -like sequence on chromosome 4 at the breakpoint of a patient with a secondary ALL. -like sequences are implicated in other leukemia causing translocations 18 but typically -like elements are noted on both chromosomes involved in the translocation. Likewise, the presence near patient 5Јs breakpoint of a 7/7 heptamer-7/9 nonamer on MLL with a 6/7 heptamer-6/9 nonamer on AF9 is suggestive of V(D)J recombinase involvement, 20 but occurs only in this single patient. It is interesting that this patient also had sequences with significant similarity to TRANSLIN binding consensus sequences at the 11q23 and 9p22 breakpoints. The TRANSLIN binding sequences described by Aoki et al 22 were found in t(8;14) and t(1;14) T cell leukemias. TRANSLIN has been shown to bind single stranded DNA and localize to the nucleus in cells treated with DNA damaging agents suggesting it has a role in DNA repair. 38 Two of the breakpoints (patients 5 and 6) fall within Alu sequences in the MLL bcr. Nonetheless, the location of the AF9 breakpoints in the same two patients outside of Alu sequences suggests homologous recombination has not mediated these translocations. Our search for a consensus sequence using either the four patients reported here or all five MLL/11q23 therapy-related leukemia patients breakpoints we have cloned did not reveal any consensus. One may not exist, but it is also possible that we analyzed an inadequate number of breakpoints.
LR-PCR may also have a role in the clinical management of patients with the t(9;11). Because of its excellent sensitivity, LR-PCR may also be useful in early detection and to search for minimal residual disease. While RT-PCR can also be used for this purpose it has disadvantages. RT-PCR uses an RNA template which is inherently less stable than DNA and because the product sizes are the same in different specimens it is more difficult to detect cross-contamination. Our results confirm that LR-PCR allows the PCR amplification of the DNA directly to produce a product of unique size for each patient. LR-PCR has also been applied to the t(2;5) 39 fusion product and several non-fusion product lymphoma-associated translocations involving immunoglobulin genes with a similar sensitivity demonstrated. 40 In conclusion, we have now analyzed the breakpoints of five patients with MLL/11q23 translocations and discovered that all have sequences similar to the Spitzner and Muller 16 topoisomerase II consensus binding sequence at or near to the breakpoint, three of these breakpoints are near the in vivo topoisomerase II cleavage site of Aplan et al. 8 These findings support the in vivo and in vitro data of other research showing epipodophyllotoxin induced cleavage of DNA at or near topoisomerase II consensus binding sequences. It remains unclear whether the presence of other recombinogenic motifs is coincidental or play a role in these translocations. Additional in vivo topoisomerase II binding and cleavage and MLL/11q23 breakpoint cloning studies are necessary to elucidate this and further our understanding of how and why these important translocations occur.
